CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
CStone Pharmaceuticals presented preclinical data on three novel antibody-drug conjugates (ADCs) at the American Association for Cancer Research (AACR) Annual Meeting. The ADCs, including CS5007, CS5006, and CS5008, were developed using CStone's proprietary ADC technology platform.
CStone Pharmaceuticals presented preclinical data for three proprietary pipeline assets at the AACR Annual Meeting. The antibody-drug conjugates (ADCs) - CS5007, CS5006, and CS5008 - were developed using CStone's proprietary ADC technology platform. CS5007 is a bispecific ADC targeting EGFR and HER3, which are key oncogenic drivers in various human epithelial malignancies. It demonstrated excellent stability, dual signaling pathway blockade, and rapid internalization. The data suggests CS5007 has potential in overcoming tumor heterogeneity and resistance mechanisms associated with single-target approaches.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.